Copenhagen, 2016-06-23 09:43 CEST (GLOBE NEWSWIRE) -- QIAGEN N.V., Company reg. no. 804803778, published a Recommended Public Conditional Voluntary Offer on 19 April 2016 (the "Offer") to the shareholders of Exiqon A/S, Company reg. no. (CVR) 18984431 (“Exiqon”). QIAGEN N.V. extended the Offer Period, according to the Offer, on 19 May 2016, on 3 June 2016 and lastly on 8 June 2016 due to a change in one of the offer conditions.
According to the Offer, the Offer Period expired yesterday on 22 June 2016 at 23.59 (CET).
In accordance with section 21(3) of the Danish Executive Order no. 562 of 2 June 2014 regarding takeover bids, etc. QIAGEN N.V. hereby announces that the Offer will be completed as well as the final result of the Offer.
QIAGEN N.V. has in total received acceptances from shareholders in Exiqon representing 34,852,938 shares and accordingly app. 94.52% of the share capital and voting rights in Exiqon.
"We are very pleased to have finally completed this transaction and will now initiate the integration process", commented Peer M. Schatz, Chief Executive Officer of QIAGEN N.V. "We welcome our new employees to the QIAGEN family and look forward to further growing the combined RNA technology offering to provide greater benefits to research and diagnostic laboratories.”
The Offer will be settled in cash through the shareholders in Exiqon's own custodian banks and will be effected as soon as possible and not later than 28 June 2016.
Immediately following completion of the Offer, QIAGEN N.V. intends to apply for a delisting of the shares of Exiqon and initiate a squeeze-out of the remaining minority shareholders.
Acquisition of Exiqon Shares after the Offer Period
QIAGEN N.V. plans to acquire further shares in Exiqon. The acquisition price for such shares shall under no circumstances exceed DKK 18 pr. share and any transaction will be carried out in accordance with Danish securities regulation.
